Marta Pratcorona

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 52 publications

Machine learning provides individualized prediction of outcomes after first complete remission without allo-HSCT consolidation in adult acute myeloid leukemia-A HARMONY study.

Machine learning provides individualized prediction of outcomes after first complete remission without allo-HSCT consolidation in adult acute myeloid leukemia-A HARMONY study.

Journal: HemaSphere

Published: February 23, 2026

ASSESSMENT OF THE IPSS-M IN CHRONIC MYELOMONOCYTIC LEUKEMIA.

ASSESSMENT OF THE IPSS-M IN CHRONIC MYELOMONOCYTIC LEUKEMIA.

Journal: Blood advances

Published: January 20, 2026

Performance and clinical utility of Spanish germ line genetic testing criteria for hematologic neoplasms predisposition.

Performance and clinical utility of Spanish germ line genetic testing criteria for hematologic neoplasms predisposition.

Journal: Blood advances

Published: October 29, 2025

Performance and Clinical Utility of Spanish Germline Genetic Testing Criteria for Hematologic Neoplasms Predisposition.

Performance and Clinical Utility of Spanish Germline Genetic Testing Criteria for Hematologic Neoplasms Predisposition.

Journal: Blood advances

Published: October 29, 2025

Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia - a HARMONY study.

Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia - a HARMONY study.

Journal: Leukemia

Published: July 24, 2025

Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations.

Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations.

Journal: Blood cancer journal

Published: February 11, 2025

Measurable Residual Disease in UBTF-TD Adult Acute Myeloid Leukemia.

Measurable Residual Disease in UBTF-TD Adult Acute Myeloid Leukemia.

Journal: European journal of haematology

Published: November 20, 2024

CD200 in acute myeloid leukemia: marked upregulation in CEBPA biallelic mutated cases.

CD200 in acute myeloid leukemia: marked upregulation in CEBPA biallelic mutated cases.

Journal: Diagnostic pathology

Published: October 22, 2024

Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group.

Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group.

Journal: Blood cancer journal

Published: October 17, 2024

Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY study.

Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY study.

Journal: Leukemia

Published: June 06, 2024

Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients.

Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients.

Journal: Journal of hematology & oncology

Published: May 19, 2024

Characterization of fusion transcripts in AML without recurrent genetic abnormalities unravels new putative fusion genes.

Characterization of fusion transcripts in AML without recurrent genetic abnormalities unravels new putative fusion genes.

Journal: Blood neoplasia

Published: May 06, 2024

Showing 1-12 of 52

Last Updated: 09/26/2026